Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.80 |
| ▸ | MEN1 | O00255 | 5/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466074 | 0.89 | KDM4E (1.00) | KDM4EMEN1KMT2AALDH1A1POLB | |
| SCHEMBL2721244 | 0.89 | KDM4E (1.00) | KDM4EMEN1KMT2AALDH1A1POLB | |
| SCHEMBL29349901 | 0.84 | KDM4E (0.90) | KDM4EMEN1KMT2AALDH1A1POLB | |
| SCHEMBL22529971 | 0.84 | KDM4E (0.90) | KDM4EMEN1KMT2AALDH1A1POLB | |
| SCHEMBL20931746 | 0.84 | KDM4E (0.79) | KDM4EMEN1KMT2AALDH1A1POLB | |
| SCHEMBL29078057 | 0.82 | MEN1 (0.60) | KDM4EMEN1KMT2AALDH1A1POLB | |
| SCHEMBL29457388 | 0.82 | MEN1 (0.60) | KDM4EMEN1KMT2AALDH1A1POLB | |
| SCHEMBL15384990 | 0.81 | MEN1 (0.59) | KDM4EMEN1KMT2AALDH1A1POLB | |
| SCHEMBL16838787 | 0.81 | MEN1 (0.59) | KDM4EMEN1KMT2AALDH1A1POLB | |
| SCHEMBL29244909 | 0.81 | MEN1 (0.58) | KDM4EMEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630525-B2 | Triazinylmethylcycloalkylcarboxylic acid derivative, and pharmaceutical composition and use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| WO-2024114663-A9 | CRYSTAL FORM OF TRIAZINYL METHYL CYCLOALKYL CARBOXYLIC ACID DERIVATIVE AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-07-18 | — | — | WO | disclosed |
| WO-2024114663-A1 | CRYSTAL FORM OF TRIAZINYL METHYL CYCLOALKYL CARBOXYLIC ACID DERIVATIVE AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-06-06 | — | — | WO | disclosed |
| EP-4349816-A1 | TRIAZINYLMETHYLCYCLOALKYLCARBOXYLIC ACID DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-117425643-A | Triazinylmethyl cycloalkyl carboxylic acid derivatives, pharmaceutical compositions and uses thereof | 上海海雁医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2022253270-A1 | TRIAZINYLMETHYLCYCLOALKYLCARBOXYLIC ACID DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海海雁医药科技有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253270-A1 | TRIAZINYLMETHYLCYCLOALKYLCARBOXYLIC ACID DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海海雁医药科技有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | SHIONOGI & CO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-9550763-B2 | Heterocyclic ring and carbocyclic derivative | SHIONOGI & CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | SHIONOGI & CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| WO-2013089212-A1 | SUBSTITUTED TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 (JP) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | P2RX3, P2RX7, P2RX2 | KDM4E 3118/4885MEN1 4224/4885KMT2A 2771/4885 |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | P2RX3, P2RX7, P2RX2 | KDM4E 3118/4885MEN1 4224/4885KMT2A 2771/4885 |
| US-12630525-B2 | Triazinylmethylcycloalkylcarboxylic acid derivative, and pharmaceutical composition and use thereof | P2RX3, P2RX1, P2RX2 | KDM4E 4577/4885MEN1 4087/4885KMT2A 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.